0.4400CAD-2.22%Mkt Cap: 36.70M CADP/E: —Last update: 2026-05-26
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap36.70M CAD
Enterprise Value26.23M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.80M CAD
Revenue/Share—
Last Price0.4400 CAD
Fiscal Year EndMar 2025
MR QuarterDec 2025
Employees18
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA-1.18
EV/Revenue—
P/S—
P/B5.95
EPS (TTM)-0.15
EPS (Forward)-0.23
52W Range
0.41801% of range1.970
52W High1.970 CAD
52W Low0.4180 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-61.82%
ROA-41.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.49M CAD
CapEx (TTM)33.00K CAD
FCF Margin—
FCF Yield-29.55%
Net Debt-10.48M CAD
Net Debt/EBITDA0.47
Balance Sheet
Debt/Equity0.01
Current Ratio2.68
Quick Ratio2.50
Book Value/Sh0.0740 CAD
Cash/Share0.1270 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 3, 2017
Analyst Consensus
Rating—
Target (Mean)3.875 CAD
Target Range3.750 CAD – 4.000 CAD
# Analysts2
Ownership
Shares Out.83.42M
Float65.95M
Insiders21.00%
Institutions0.00%
Short Interest
Short Ratio0.8d
Short % Float0.28%
Short % Out.0.10%
Shares Short83.30K
Short (prev mo.)164.51K
Technical
SMA 500.6300 (-30.2%)
SMA 2000.9715 (-54.7%)
Beta1.91
S&P 52W Chg28.31%
Avg Vol (30d)146.48K
Avg Vol (10d)185.98K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—